A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety and Tolerability of LPT99 Administered to Healthy Adult Subjects
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 26 Aug 2019
Price : $35 *
At a glance
- Drugs LPT 99 (Primary)
- Indications Hearing loss
- Focus Adverse reactions
- Sponsors Spiral Therapeutics
- 22 Aug 2019 Planned End Date changed from 9 Apr 2019 to 20 Sep 2019.
- 22 Aug 2019 Status changed from recruiting to active, no longer recruiting.
- 18 Dec 2018 According to a Spiral Therapeutics media release, this study to complete the study by the second quarter of 2019.